Immunovaccine is a clinical-stage vaccine development company focused on advancing its patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy and infectious diseases.
Immunovaccine’s pipeline also includes a broad range of infectious diseases programs including vaccines in such indications as respiratory syncytial virus (RSV) and anthrax. In addition to the company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications.
Partnerships represent an essential element of Immunovaccine’s business strategy and the company’s collaborators include many leaders in their respective areas of focus including the National Institutes of Health and Zoetis (formerly Pfizer Animal Health).
To learn more about Immunovaccine visit their website at https://www.imvaccine.com/index.php